Cxcr4 inhibitors and uses thereof

Abstract

The present invention provides compounds, compositions thereof, and methods of using the same.

We claim: 
     
         1 - 32 . (canceled) 
     
     
         33 . A compound of Formula VII-a: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, wherein: 
         each R 1  is independently R, halogen, —CN, —OR, —N(R) 2 , —NO 2 , —N 3 , —SR, or -L 1 -R 6 ; 
         each R is independently hydrogen or an optionally substituted group selected from C 1-6  aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; 
         each L 1  and L 2  is independently a covalent bond or a C 1-8  bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with —O—, —C(O)—, —C(O)O—, —OC(O)—, —N(R)—, —C(O)N(R)—, —(R)NC(O)—, —OC(O)N(R)—, —(R)NC(O)O—, —N(R)C(O)N(R)—, —S—, —SO—, —SO 2 —, —SO 2 N(R)—, —(R)NSO 2 —, —C(S)—, —C(S)O—, —OC(S)—, —C(S)N(R)—, —(R)NC(S)—, —(R)NC(S)N(R)—, or -Cy-; 
         each -Cy- is independently a bivalent optionally substituted 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, optionally substituted phenylene, an optionally substituted 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, an optionally substituted 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, an optionally substituted 8-10 membered bicyclic or bridged bicyclic saturated or partially unsaturated heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 8-10 membered bicyclic or bridged bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; 
         R 2  is hydrogen, -L 2 -R 6 , or optionally substituted C 1-8  aliphatic; 
         R 3  is hydrogen, optionally substituted C 1-6  aliphatic, or -L 3 -R 6 ; 
         L 3  is a C 1-6  bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with —O—, —C(O)—, —C(O)O—, —OC(O)—, —N(R)—, —C(O)N(R)—, —(R)NC(O)—, —S—, —SO—, —SO 2 —, —C(S)—, or -Cy-; 
         each R 4  is independently hydrogen, deuterium, halogen, —CN, —OR 6 , or C 1-4  alkyl, or two R 4  groups on the same carbon are optionally taken together to form ═NR 6 , ═NOR 6 , ═O, or ═S; 
         each R 5  is independently R, halogen, —CN, —OR, —N(R) 2 , —NO 2 , —N 3 , —SR, or -L 1 -R 6 , or two R 5  groups on the same saturated carbon atom are optionally taken together to form ═NR, ═NOR, ═O, ═S, or a spirocyclic 3-6 membered carbocyclic ring; 
         each R 6  is independently hydrogen or C 1-6  alkyl optionally substituted with 1, 2, 3, 4, 5, or 6 deuterium or halogen atoms; 
         m is 0, 1, 2, 3, or 4; 
         n is 0, 1, 2, 3, or 4; and 
         p is 0, 1, 2, 3, or 4. 
       
     
     
         34 . The compound of  claim 33 , wherein R 1  is selected from hydrogen, halogen, C 1-6  alkyl (optionally substituted with 1, 2, or 3 halogens), —CN, —N(R) 2 , —OR, —SR, —S(O)R 6 , —SO 2 R, —SO 2 NR 6 , 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
       and each R is independently hydrogen, —CH 2 -phenyl, phenyl, C 1-6  alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, —CH 2 F, —CHF 2 , —CF 3 , —CH 2 CHF 2 , or —CH 2 CF 3 . 
     
     
         35 . The compound of  claim 33 , wherein L 1  is a C 1-6  bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with —O—, —C(O)—, —N(R)—, —S—, —SO—, —SO 2 —, —SO 2 N(R)—, —(R)NSO 2 —, —C(S)—, or -Cy-, wherein each R is independently hydrogen, —CH 2 -phenyl, phenyl, C 1-6  alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, —CH 2 F, —CHF 2 , —CF 3 , —CH 2 CHF 2 , or —CH 2 CF 3 . 
     
     
         36 . The compound of  claim 33 , wherein L 2  is a C 1-6  bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with —O—, —C(O)—, —N(R)—, —S—, —SO—, —SO 2 —, —SO 2 N(R)—, —(R)NSO 2 —, —C(S)—, or -Cy-, and each R is independently hydrogen, —CH 2 -phenyl, phenyl, C 1-6  alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, —CH 2 F, —CHF 2 , —CF 3 , —CH 2 CHF 2 , or —CH 2 CF 3 . 
     
     
         37 . The compound of  claim 33 , wherein -Cy- is 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         38 . The compound of  claim 33 , wherein R 2  is selected from hydrogen, C 1-6  alkyl (optionally substituted with 1, 2, or 3 halogens), —S(O)R 6 , —SO 2 R 6 , —SO 2 NHR 6 , —(CH 2 ) 1-6 —N(R)R 6 , —(CH 2 ) 1-6 —OR 6 , or —(CH 2 ) 0-6 -Cy-R 6 . 
     
     
         39 . The compound of  claim 38 , wherein R 2  is selected from hydrogen, —S(O)R 6 , —SO 2 R 6 , —SO 2 NHR 6 , —(CH 2 ) 1-6 —N(R)R 6 , —(CH 2 ) 1-6 —OR 6 , 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
       and each R is independently hydrogen, —CH 2 -phenyl, phenyl, C 1-6  alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, —CH 2 F, —CHF 2 , —CF 3 , —CH 2 CHF 2 , or —CH 2 CF 3 . 
     
     
         40 . The compound of  claim 33 , wherein R 3  is selected from hydrogen or C 1-6  alkyl (optionally substituted with 1, 2, or 3 deuterium or halogen atoms), —(CH 2 ) 1-6 —CN, —(CH 2 ) 1-6 —N(R)(R 6 ), —(CH 2 ) 1-6 —OR 6 , 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
       and each R is independently hydrogen, —CH 2 -phenyl, phenyl, C 1-6  alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, —CH 2 F, —CHF 2 , —CF 3 , —CH 2 CHF 2 , or —CH 2 CF 3 . 
     
     
         41 . The compound of  claim 40 , wherein R 3  is hydrogen or C 1-4  alkyl optionally substituted with 
       
         
           
           
               
               
           
         
       
       pyridyl, —N(R) 2 , —CN, or 1, 2, or 3 deuterium or halogen atoms, wherein R is hydrogen or C 1-3  alkyl. 
     
     
         42 . The compound of  claim 41 , wherein R 3  is methyl. 
     
     
         43 . The compound of  claim 33 , wherein R 4  is hydrogen, deuterium, halogen, —CN, or C 1-2  alkyl; or two instances of R 4  taken together are ═O or ═S. 
     
     
         44 . The compound of  claim 33 , wherein R 5  is hydrogen, C 1-6  alkyl, halogen, —CN, —OCF 3 , cyclopropyl, ethynyl, —OCH 3 , —CF 3 , —CD 3 , or 
       
         
           
           
               
               
           
         
       
     
     
         45 . The compound of  claim 33 , wherein the compound is represented by Formula VII-b or VII-c: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         46 . The compound of  claim 33 , wherein the compound is represented by Formula VIII-a, VIII-b, VIII-c, VIII-d, or VIII-e: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         47 . The compound of  claim 46 , wherein the compound is represented by Formula IX 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         48 . The compound of  claim 47 , wherein the compound is represented by Formula X-a or X-b: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         49 . A compound of Formula XII: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, wherein: 
         Ring A is 
       
       
         
           
           
               
               
           
         
         each R 1  is independently R, halogen, —CN, —OR, —N(R) 2 , —NO 2 , —N 3 , —SR, or -L 1 -R 6 ; 
         each R is independently hydrogen or an optionally substituted group selected from C 1-6  aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; 
         each L 1  and L 2  is independently a covalent bond or a C 1-8  bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with —O—, —C(O)—, —C(O)O—, —OC(O)—, —N(R)—, —C(O)N(R)—, —(R)NC(O)—, —OC(O)N(R)—, —(R)NC(O)O—, —N(R)C(O)N(R)—, —S—, —SO—, —SO 2 —, —SO 2 N(R)—, —(R)NSO 2 —, —C(S)—, —C(S)O—, —OC(S)—, —C(S)N(R)—, —(R)NC(S)—, —(R)NC(S)N(R)—, or -Cy-; 
         each -Cy- is independently a bivalent optionally substituted 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, optionally substituted phenylene, an optionally substituted 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, an optionally substituted 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, an optionally substituted 8-10 membered bicyclic or bridged bicyclic saturated or partially unsaturated heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 8-10 membered bicyclic or bridged bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; 
         R 2  is hydrogen, -L 2 -R 6 , or optionally substituted C 1-8  aliphatic; 
         R 3  is hydrogen, optionally substituted C 1-6  aliphatic, or -L 3 -R 6 ; 
         L 3  is a C 1-6  bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with —O—, —C(O)—, —C(O)O—, —OC(O)—, —N(R)—, —C(O)N(R)—, —(R)NC(O)—, —S—, —SO—, —SO 2 —, —C(S)—, or -Cy-; 
         each R 4  is independently hydrogen, deuterium, halogen, —CN, —OR 6 , or C 1-4  alkyl, or two R 4  groups on the same carbon are optionally taken together to form ═NR 6 , ═NOR 6 , ═O, or ═S; 
         each R 5  is independently R, halogen, —CN, —OR, —N(R) 2 , —NO 2 , —N 3 , —SR, or -L 1 -R 6 , or two R 5  groups on the same saturated carbon atom are optionally taken together to form ═NR, ═NOR, ═O, ═S, or a spirocyclic 3-6 membered carbocyclic ring; 
         each R 6  is independently hydrogen or C 1-6  alkyl optionally substituted with 1, 2, 3, 4, 5, or 6 deuterium or halogen atoms; 
         m is 0, 1, or 2; 
         n is 0, 1, 2, 3, or 4; and 
         p is 0, 1, 2, 3, or 4. 
       
     
     
         50 . A pharmaceutical composition comprising a compound of  claim 33  and a pharmaceutically acceptable excipient. 
     
     
         51 . A pharmaceutical composition comprising a compound of  claim 49  and a pharmaceutically acceptable excipient. 
     
     
         52 . A compound selected from: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         53 . A method of treating a primary immunodeficiency disease or disorder, comprising administering to a patient in need thereof an effective amount of a compound of  claim 33 , or a pharmaceutically acceptable salt thereof. 
     
     
         54 . The method of  claim 53 , wherein the primary immunodeficiency disease or disorder is warts, hypogammaglobulinemia, infections, myelokathexis (WHIMs) syndrome; severe congenital neutropenia (SCN); GATA2 deficiency (Mono MAC syndrome); idiopathic CD4+ T lymphocytopenia (ICL); or Wiskott-Aldrich Syndrome. 
     
     
         55 . The method of  claim 53 , wherein the primary immunodeficiency disease or disorder is warts, hypogammaglobulinemia, infections, myelokathexis (WHIMs) syndrome.